Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27774530 | 1.00 | HDAC4 (0.50) | HDAC4AKR1C1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1953126 | 0.98 | AKR1C1 (0.50) | HDAC4AKR1C1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1612406 | 0.82 | HDAC4 (0.47) | HDAC4AKR1C1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13222778 | 0.80 | SLC6A2 (0.49) | HDAC4AKR1C1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27296884 | 0.80 | HDAC4 (0.46) | HDAC4AKR1C1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL290573 | 0.79 | OPRM1 (0.46) | HDAC4SLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL14899045 | 0.78 | AKR1C1 (0.48) | HDAC4AKR1C1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8655542 | 0.77 | SLC6A4 (0.54) | HDAC4AKR1C1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28776197 | 0.76 | SLC6A4 (0.50) | HDAC4AKR1C1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6669439 | 0.76 | HDAC4 (0.49) | HDAC4AKR1C1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4297725-B1 | SYRINGE STERILIZATION METHOD | FARCO GMBH (DE) | 2024-10-23 | — | — | EP | claimed |
| EP-4360669-A2 | METHOD FOR SYRINGE STERILIZATION | Farco-Pharma GmbH (DE) | 2024-05-01 | — | — | EP | claimed |
| EP-4297725-A1 | SYRINGE STERILIZATION METHOD | Farco-Pharma GmbH (DE) | 2024-01-03 | — | — | EP | claimed |
| WO-2022223174-A1 | SYRINGE STERILIZATION METHOD | FARCO-PHARMA GMBH (DE) | 2022-10-27 | — | — | WO | claimed |
| US-10449173-B2 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions | ALLERGAN SALES, LLC (US) | 2019-10-22 | — | — | US | claimed |
| EP-3287122-B1 | DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS FOR TREATING OVERACTIVE BLADDERS. | ALLERGAN SALES LLC (US) | 2019-04-17 | — | — | EP | claimed |
| EP-3287122-A1 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | Allergan Sales, LLC (US) | 2018-02-28 | — | — | EP | claimed |
| EP-2427172-B1 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | ALLERGAN SALES LLC (US) | 2017-11-01 | — | — | EP | claimed |
| US-20160128963-A1 | METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | WATSON LABORATORIES, INC. | 2016-05-12 | — | — | US | claimed |
| US-9259388-B2 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions | WATSON PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | claimed |
| US-8920392-B2 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions | WATSON LABORATORIES, INC. (US) | 2014-12-30 | — | — | US | claimed |
| US-20140046275-A1 | Method for Treating Overactive Bladders and a Device for Storage and Administration of Topical Oxybutynin Compositions | WATSON LABORATORIES, INC. (US) | 2014-02-13 | — | — | US | claimed |
| EP-2427172-A2 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | Watson Laboratories, Inc. (US) | 2012-03-14 | — | — | EP | claimed |
| WO-2010129498-A2 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | WATSON LABORATORIES, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100286630-A1 | Method For Treating Overactive Bladders And A Device For Storage And Administration Of Topical Oxybutynin Compositions | WATSON LABORATORIES, INC. (US) | 2010-11-11 | — | — | US | claimed |
| EP-4297725-B1 | SYRINGE STERILIZATION METHOD | FARCO GMBH (DE) | 2024-10-23 | — | — | EP | disclosed |
| EP-4415790-A1 | SYRINGE WITH INTEGRATED ADAPTER | Farco-Pharma GmbH (DE) | 2024-08-21 | — | — | EP | disclosed |
| CN-1396829-A | Novel pharmaceutical combination | PHARMACIA & UPJOHN (US) | 2003-02-12 | — | — | CN | disclosed |
| US-4784857-A | Drug delivery device, its preparation and use | SMITH AND NEPHEW ASSOCIATED COMPANIES PLC (GB) | 1988-11-15 | — | — | US | disclosed |
| EP-0140434-A2 | Pharmaceutical composition with systemic anticholineesterasic, agonistic-cholinergic and antimuscarinic activity | PRODOTTI FORMENTI S.r.l. (IT) | 1985-05-08 | — | — | EP | disclosed |